Smiths Detection Launches CORSYS: The Future of Integrated Security for Ports and Borders in the Palm of Your Hand
Smiths Detection is proud to unveil its pioneering enterprise-level security command centre, CORSYS – a secure, cloud-based, digital ecosystem that integrates data from a vast array of devices and processes, to support critical ports and borders security.
CORSYS’ ability to consolidate information into a single command centre display eliminates the need for security operations managers to access multiple, independent bespoke systems to obtain the information they require.
The SaaS-based software product is a hardware-agnostic system that is fully mobile responsive/enabled. By allowing users to control their entire security operation from a single, secure window it supports real-time awareness and rapid decision-making. Following development, rigorous testing and extensive customer journey-mapping workshops have ensured CORSYS offers ease of use and the highest levels of security.
It has been developed specifically for Business to Government operations and will be officially unveiled at the World Customs Organization’s Global Technology and Innovation Forum in Japan this week (31 October - 2 November 2017).
“CORSYS uses the latest digital architecture – including stream analytics, machine learning; and augmented intelligence – to aggregate data from a customer’s stable of IoT devices, in order to assess anomalies, detect risks and improve outcomes,” said Smiths Detection’s Global Market Director for Ports & Borders, Tim Norton.
He added: “In a ports and borders application, CORSYS can provide an overall view of the entire port, as well as assessing every single container. It can view data from an electronic manifest and help customs administrators generate a risk profile for each container arriving at a port, using a combination of physical and data-driven tools. It also integrates smart CCTV and third-party data sources.”
CORSYS has been designed to help Customs Administrators identify anomalies, manage risks more effectively and increase duty collections to significantly improve overall operational performance.
CORSYS can integrate three aspects of an organisation’s security operations:
1. Devices: including screening and detection equipment; perimeter security; access control; surveillance equipment; and communications networks
2. Processes: including manifest examination; screening decision-making; physical inspection communications; and process flow (for containers/parcels), as well as maintenance planning and execution
3. Oversight tools: including asset management and performance dashboards
The CORSYS architecture is based on an open, hardware-agnostic platform designed with Microsoft Azure as its core SaaS delivery service. It is developed on globally accepted technology, with government-level disaster recovery, that is positioned for large-scale enterprises.
As Smiths Detection’s Tim Norton highlights: “The PROFILER application, for example, uses machine learning algorithms to determine the most efficient way to physically inspect targets – be that non-intrusive inspection (such as X-ray scanning), canine inspection or destuffing (unloading) the container. The ANALYSER+ application enhances the ability to recognise threats and contraband, while the DECISION CENTRE & DASHBOARD applications allow officers to monitor the entire flow of their security operations from a single window.”
Following its launch at the 2017 World Customs Organization’s Global Technology and Innovation Forum, CORSYS will be available to purchase in Q1 2018. To learn more, please visit www.corsys.com for the latest information.
About Smiths Detection
Smiths Detection is a global leader in threat detection and screening technologies for the military, air transportation, homeland security and emergency response sectors. Our experience and history across more than 40 years at the frontline, enables us to provide unrivalled levels of expertise to detect and identify constantly changing chemical, biological, radiological, nuclear and explosive threats, as well as weapons, contraband and narcotics.
Our goal is simple - to provide the security, peace of mind and freedom of movement upon which the world depends. For more information visit www.smithsdetection.com
Smiths Detection is part of Smiths Group, a global technology company listed on the London Stock Exchange. A world leader in the practical application of advanced technologies, Smiths Group delivers products and services for the threat and contraband detection, medical devices, energy and communications markets worldwide, employing more than 22,000 people in over 50 countries. For more information visit www.smiths.com.
Director Communications and Marketing (EMEA)
+49 (0)611 9412 422
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting21.10.2018 01:30 | Tiedote
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 20:37 | Tiedote
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 16:10 | Tiedote
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 15:00 | Tiedote
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an
Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene19.10.2018 14:54 | Tiedote
Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients aged 12 to <24 months, who have specific mutations in the CFTR gene. “Cystic fibrosis is a chronic, progressive disease that is present at birth, with symptoms often occurring in infancy, so early treatment is crucial to deliver the best possible outcomes for patients,” said Reshma Kewalr
Tradeshift Announces Q3 2018 Results19.10.2018 14:00 | Tiedote
Tradeshift, the leader in supply chain payments and marketplaces, today announced results from the third quarter of 2018, marking the tenth quarter in a row of successive growth and beating targets. Tradeshift’s third quarter growth stats announced today include: YoY revenue grew 400 percent (trailing 12 months) YoY new bookings grew 284 percent YoY gross merchandise volume (GMV) grew 262 percent New total contract value grew by $47M in Q3 Tradeshift’s customer roster continued strong growth this quarter adding 27 new customers, including Hertz, Shiseido, ECU, and Fortune 500 leaders in retail apparel, agriculture, engineering and construction, hospitality, travel and food delivery. Tradeshift also expanded its app ecosystem by adding a key partnership with Coface, a global credit insurer. Coface has announced a new app solution on the Tradeshift platform offering risk and business information services to help businesses make decisions by ensuring greater financial transparency between
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme